Table 3. Details on pembrolizumab administration in cases of dMMR detection.
dMMR, mismatch repair gene deficiency; CGP, comprehensive genomic profiling; MSI-H, microsatellite instability-high; TMB-high, high tumor mutation burden; CRPC-NE, castration-resistant neuroendocrine prostate cancer; CRPC, castration-resistant prostate cancer
| Patient | Age | Primary disease | Prior lines of therapy | Kit used for dMMR evaluation | Types of detected dMMR | Other genetic mutations detected on CGP | Time to next line of therapy (months) | Immune-related adverse events |
| 1 | 65 y | CRPC-NE | 3 | MSI-IVD | MSI-H | N/A | N/A | None |
| 2 | 73 y | CRPC | 3 | F1CDx | TMB-high | BRCA2 L1908fs*2, PTEN D58fs*7 | 1.5 | None |
| 3 | 67 y | CRPC | 2 | F1CDx | MSI-H, TMB-high | BRCA2 T3033fs*11, ATM K2811fs*46, CHEK1 T226fs*14, ARID1A D1850fs*33, PIK3CA G122D/R93Q/D350G, PTEN T319fs*1/R173H/V290fs*1 | 1.5 | Interstitial pneumonia (CTCAE v5.0 grade 3) |
| 4 | 77 y | CRPC | 3 | NOP | TMB-high | Not detected | N/A | N/A |